![]() |
Name |
(Z)-9-Hexadecenal
|
Molecular Formula | C16H30O | |
IUPAC Name* |
(Z)-hexadec-9-enal
|
|
SMILES |
CCCCCC/C=C\CCCCCCCC=O
|
|
InChI |
InChI=1S/C16H30O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17/h7-8,16H,2-6,9-15H2,1H3/b8-7-
|
|
InChIKey |
QFPVVMKZTVQDTL-FPLPWBNLSA-N
|
|
Synonyms |
(Z)-Hexadec-9-enal; (Z)-9-Hexadecenal; 56219-04-6; cis-9-Hexadecenal; 9Z-Hexadecenal; 9-Hexadecenal, (9Z)-; Z-9-HEXADECENAL; 9-Hexadecenal, (Z)-; NXO9ML6I2E; (9Z)-9-Hexadecenal; EINECS 260-064-2; UNII-NXO9ML6I2E; (9Z)-9-Hexadecenal #; SCHEMBL556941; (9Z)-HEXADEC-9-ENAL; HEXADECENAL, (Z)-9-; DTXSID5041194; CIS-9-HEXADECENAL, 95; CHEBI:179683; 9Z-HEXADECEN/AL , 95 %; LMFA06000217; ZINC59725570; 9Z-Hexadecenal CAS 56219-04-6; Q27285093; 81K
|
|
CAS | 56219-04-6 | |
PubChem CID | 5364643 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 238.41 | ALogp: | 6.1 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 13 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 17.1 | Aromatic Rings: | 0 |
Heavy Atoms: | 17 | QED Weighted: | 0.23 |
Caco-2 Permeability: | -4.807 | MDCK Permeability: | 0.00002290 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.998 |
30% Bioavailability (F30%): | 0.999 |
Blood-Brain-Barrier Penetration (BBB): | 0.884 | Plasma Protein Binding (PPB): | 89.41% |
Volume Distribution (VD): | 3.735 | Fu: | 2.94% |
CYP1A2-inhibitor: | 0.362 | CYP1A2-substrate: | 0.269 |
CYP2C19-inhibitor: | 0.394 | CYP2C19-substrate: | 0.076 |
CYP2C9-inhibitor: | 0.252 | CYP2C9-substrate: | 0.932 |
CYP2D6-inhibitor: | 0.446 | CYP2D6-substrate: | 0.706 |
CYP3A4-inhibitor: | 0.412 | CYP3A4-substrate: | 0.076 |
Clearance (CL): | 3.858 | Half-life (T1/2): | 0.742 |
hERG Blockers: | 0.385 | Human Hepatotoxicity (H-HT): | 0.032 |
Drug-inuced Liver Injury (DILI): | 0.033 | AMES Toxicity: | 0.168 |
Rat Oral Acute Toxicity: | 0.021 | Maximum Recommended Daily Dose: | 0.043 |
Skin Sensitization: | 0.976 | Carcinogencity: | 0.296 |
Eye Corrosion: | 0.988 | Eye Irritation: | 0.989 |
Respiratory Toxicity: | 0.939 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001686 | ![]() |
0.825 | D0O1PH | ![]() |
0.575 | ||
ENC001690 | ![]() |
0.759 | D0O1TC | ![]() |
0.534 | ||
ENC001713 | ![]() |
0.733 | D0OR6A | ![]() |
0.461 | ||
ENC001099 | ![]() |
0.724 | D0UE9X | ![]() |
0.452 | ||
ENC002845 | ![]() |
0.724 | D05ATI | ![]() |
0.433 | ||
ENC001589 | ![]() |
0.724 | D0Z5SM | ![]() |
0.411 | ||
ENC001435 | ![]() |
0.689 | D07ILQ | ![]() |
0.380 | ||
ENC000277 | ![]() |
0.686 | D0Z5BC | ![]() |
0.349 | ||
ENC000607 | ![]() |
0.673 | D09SRR | ![]() |
0.348 | ||
ENC001666 | ![]() |
0.661 | D00AOJ | ![]() |
0.333 |